gene therapy
DESCRIPTION
A comprehensive guideTRANSCRIPT
![Page 1: Gene Therapy](https://reader036.vdocument.in/reader036/viewer/2022062819/577c77461a28abe0548b6fe9/html5/thumbnails/1.jpg)
Gene Therapy: The current solution for many dreadful diseases.
Soumyadip Das,Graduate student, Dept. of Biomedical Sc. & Engineering
Hanyang University, SeoulAdvisor: Dr. Suresh Ramakrishna.
![Page 2: Gene Therapy](https://reader036.vdocument.in/reader036/viewer/2022062819/577c77461a28abe0548b6fe9/html5/thumbnails/2.jpg)
Gene therapy:Gene therapy is the technology in which any gene, which is responsible for the development of a disease, is replaced with a healthy gene.
The gene therapy can be performed with the aim of gene editing accordingly,
A. Replacing a mutated gene that causes disease with a healthy copy of the gene.
B.Inactivating, or “knocking out,” a mutated gene that is functioning improperly.
C.Introducing a new gene into the body to help to fight against a disease.
![Page 3: Gene Therapy](https://reader036.vdocument.in/reader036/viewer/2022062819/577c77461a28abe0548b6fe9/html5/thumbnails/3.jpg)
Gene Editing:The gene editing can be performed with the help of artificial programmable nucleases or in other words restriction enzymes, which produce site specific DNA-double strand break which leads to mutagenesis. Types of nucleases:I.Zinc finger nucleases (ZFN’s)
II.Transcription activator-like effector nucleases (TALENs)
III.RNA-guided engineered nucleases (RGENs)/CRISPR Cas9 system
![Page 4: Gene Therapy](https://reader036.vdocument.in/reader036/viewer/2022062819/577c77461a28abe0548b6fe9/html5/thumbnails/4.jpg)
Zinc-finger nucleases: (First generation nucleases)
Artificial restriction enzyme and have two domains;
DNA binding domain,genetically engineered to bind to specific site of DNA. It can recognise between 9-18 bp.
DNA cleaving domain,Fokl restriction enzymeused for cleavage of DNA.
![Page 5: Gene Therapy](https://reader036.vdocument.in/reader036/viewer/2022062819/577c77461a28abe0548b6fe9/html5/thumbnails/5.jpg)
Transcription-activator like effector nuclease (TALENs): Second generation nucleaseArtificial restrition enzyme generated by fusion of,
transcription activator (TAL) proteins or DNA binding domain
DNA cleaving domain (Fokl nuclease)
![Page 6: Gene Therapy](https://reader036.vdocument.in/reader036/viewer/2022062819/577c77461a28abe0548b6fe9/html5/thumbnails/6.jpg)
CRISPR/Cas9 (cluster regularly interspaced short palindromic repeat):Targeting RNA : CRISPR RNA Trans-CRISPR RNA
Cas9 protein: Which cleaves or break the double strands and induce a mutation.
![Page 7: Gene Therapy](https://reader036.vdocument.in/reader036/viewer/2022062819/577c77461a28abe0548b6fe9/html5/thumbnails/7.jpg)
![Page 8: Gene Therapy](https://reader036.vdocument.in/reader036/viewer/2022062819/577c77461a28abe0548b6fe9/html5/thumbnails/8.jpg)
Overlapped Extension PCR:
1. To Insert specific mutation at specific points in a sequence.
2.To splice (join) two smaller DNA fragments into larger polynucleotide.
![Page 9: Gene Therapy](https://reader036.vdocument.in/reader036/viewer/2022062819/577c77461a28abe0548b6fe9/html5/thumbnails/9.jpg)
![Page 10: Gene Therapy](https://reader036.vdocument.in/reader036/viewer/2022062819/577c77461a28abe0548b6fe9/html5/thumbnails/10.jpg)
After 1st PCR with Primers a+b and c+d,
We could see two fragments of definite sizes.
After 2nd PCR with primers a+d,
We could differentiate and understand whether the overlapping has happened or not, by determining the size of the band.
Kbp
20001000500
![Page 11: Gene Therapy](https://reader036.vdocument.in/reader036/viewer/2022062819/577c77461a28abe0548b6fe9/html5/thumbnails/11.jpg)
![Page 12: Gene Therapy](https://reader036.vdocument.in/reader036/viewer/2022062819/577c77461a28abe0548b6fe9/html5/thumbnails/12.jpg)
1.Transformation.2.Incubation overnight at 37 degree centigrade.3.Colonies.4.Screening those colonies (colony PCR).5.Positive colonies are Inoculated in growth media.6.Mini-prep of the Positive colonies. Send those for sequencing.
![Page 13: Gene Therapy](https://reader036.vdocument.in/reader036/viewer/2022062819/577c77461a28abe0548b6fe9/html5/thumbnails/13.jpg)